ArticleVaccine2020
Planning for COVID-19 vaccines safety surveillance.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 87 citations in OpenAlex.
- Establishing a Multicenter Active Adverse Events Following Immunization Sentinel Surveillance Network Across 22 Tertiary Care Hospitals in India: Protocol for a Prospective Observational Study.JMIR research protocols · 2025Article
- Building functional and sustainable pharmacovigilance systems: an analysis of pharmacovigilance development across high-, middle- and low-income countries.Therapeutic advances in drug safety · 2025Article
- A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study.Human vaccines & immunotherapeutics · 2024Article
- Immediate adverse events following immunization (AEFI) in drive-through COVID-19 vaccination campaign in Yogyakarta, Indonesia: A cross-sectional study.The Indian journal of medical research · 2024Article
- Detection of SARS-CoV-2 Variants Imported Through Land Borders at the Height of the COVID-19 Pandemic in Ghana, 2022.Cureus · 2024Article
- Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India.Journal of family medicine and primary care · 2024Article
- A Comparison of COVID-19 Vaccine and PrEP Hesitancy Among Individuals Living in Mississippi: A Qualitative Study.AIDS and behavior · 2023Article
- Observational Study of Patients Hospitalized With Neurologic Events After SARS-CoV-2 Vaccination, December 2020-June 2021.Neurology. Clinical practice · 2023Article
- Manifestations of adverse events post Sinovac vaccine immunization at Wirasakti Hospital, Kupang.Journal of public health in Africa · 2023Article
- Intervention Analysis of COVID-19 Vaccination in Nigeria: The Naive Solution Versus Interrupted Time Series.Annals of data science · 2023Review
- Impact of risk communication on patient's safety during the pandemic.Therapeutic advances in drug safety · 2023Review
- COVID-19 Vaccines, Effectiveness, and Immune Responses.International journal of molecular sciences · 2022Review
- Adverse reactions to inactivated COVID-19 vaccination in patients with chronic liver disease: The effect of anxiety.Human vaccines & immunotherapeutics · 2022Article
- A comparison of seasonal influenza and novel Covid-19 vaccine intentions: A cross-sectional survey of vaccine hesitant adults in England during the 2020 pandemic.Human vaccines & immunotherapeutics · 2022Article
- Positive perception of COVID-19 vaccination in HAE: No significant impact of vaccination on disease course.Allergy and asthma proceedings · 2022Article
- Article
- Article
- Article
- Leukocytoclastic Vasculitis Following COVID-19 Vaccination: A Case Report.Hospital pharmacy · 2022Article
- COVID-19 Vaccination and The Eye.American journal of ophthalmology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 vaccines are the most important tool to stem the pandemic. They are being developed with unprecedented global collaboration and accelerated timelines to achieve WHO Emergency Use Listing, while using regulatory pathways through national regulatory authorities. Alongside preparations to ensure equitable access to the vaccines among people globally, preparations must be made within countries for COVID-19 vaccines safety surveillance on an urgent basis. Safety surveillance must be capable of investigating adverse events of special interest (AESI) and adverse events following immunization to determine a change in the benefit-risk profile of the vaccine, and to be able to anticipate coincidental events that might be attributed to the vaccine. Active surveillance systems should calculate the incidence of background rates of AESI prior to vaccine roll out. These background rates vary tremendously across regions, populations and case ascertainment methods. Active surveillance systems must be established or strengthened now, (including in LMIC), to calculate the background rates. Utilizing standardized case definitions and global standards for AESI will help in harmonization. Vaccine safety communication plans should be developed. Expanding the global vaccine safety system to meet the needs of COVID-19 and other emergency and routine use vaccines is a priority currently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.